Related Experiment Video

Updated: Aug 18, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells

Tao Zhang1, Ming Guan, Hong Yan Jin

  • 1Center of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.

Gynecologic Oncology
|May 3, 2005
PubMed
Abstract

Insights

Small interfering RNAs (siRNAs) targeting p-glycoprotein (P-gp) and glutathione S-transferases (GST) effectively reduced drug resistance in ovarian cancer cells. This approach restored sensitivity to cisplatin chemotherapy, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cisplatin resistance is a significant challenge in ovarian cancer chemotherapy.
  • Overcoming multidrug resistance (MDR) is crucial for improving treatment outcomes.

Purpose of the Study:

  • To investigate the efficacy of siRNAs targeting p-glycoprotein (P-gp) and glutathione S-transferases (GST) in cisplatin-resistant ovarian cancer cells.
  • To determine if these siRNAs can restore sensitivity to cisplatin (DDP).

Main Methods:

  • siRNAs were designed to target P-gp and GST mRNA.
  • Real-Time PCR and western blotting were used to assess gene and protein expression.
  • Ovarian cancer cell lines (COC1/DDP and SKOV3/DDP) were transfected with siRNAs.

Main Results:

  • siRNA transfection led to time-dependent inhibition of P-gp and GST expression.
  • This inhibition decreased IC50 values, indicating restored sensitivity to DDP.
  • siRNA treatment enhanced intracellular DDP accumulation and reversed drug resistance.

Conclusions:

  • P-gp and GST siRNAs are effective inhibitors of MDR gene expression in ovarian cancer.
  • siRNAs can reverse cisplatin resistance in ovarian carcinomas.
  • This research suggests siRNAs as a potential novel therapeutic tool for ovarian cancer treatment.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...